Detalhe da pesquisa
1.
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
JAMA Oncol
; 10(5): 603-611, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546612
2.
Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy.
Breast Cancer Res Treat
; 172(1): 239-240, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30003394
3.
Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: a single-center experience with 31 patients.
Int J Urol
; 20(5): 478-83, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23113655
4.
Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges.
J Clin Med
; 12(3)2023 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36769602
5.
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00.
Clin Cancer Res
; 29(23): 4908-4919, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37733800
6.
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Nat Commun
; 14(1): 7053, 2023 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37923752
7.
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis.
NPJ Breast Cancer
; 8(1): 79, 2022 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35790747
8.
Timing evolution of lobular breast cancer through phylogenetic analysis.
EBioMedicine
; 82: 104169, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35882101
9.
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.
Cancers (Basel)
; 13(11)2021 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34198891
10.
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
Clin Cancer Res
; 27(20): 5607-5618, 2021 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34321278
11.
Characterizing CDK12-Mutated Prostate Cancers.
Clin Cancer Res
; 27(2): 566-574, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988971
12.
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Oncoimmunology
; 9(1): 1832348, 2020 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33178494
13.
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.
Eur Urol Oncol
; 3(2): 176-182, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31307958
14.
Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report.
Anticancer Res
; 34(2): 905-7, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24511030